Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Phase I/II Two Center Safety and Tolerability Study
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Nov 2018
At a glance
- Drugs Tofacitinib (Primary)
- Indications Systemic scleroderma
- Focus Adverse reactions
- Acronyms TOFA-SSc
- 14 Nov 2018 Planned End Date changed from 1 Apr 2020 to 1 Dec 2019.
- 14 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
- 04 Sep 2018 Status changed from recruiting to active, no longer recruiting.